TB Alliance

A persistent shortfall in TB research and development funding

NEW YORK (April 15, 2021) — The 2020 G-Finder Report, released today, shows that low funding levels are putting life-saving science—and especially the most vulnerable—at risk. Global investments in tuberculosis (TB) research and development (R&D) funding totaled of $670 million in 2019. This is far short of the estimated $2.16 billion that the Stop TB Partnership estimates is needed annually to develop and deliver new tools that can end the TB pandemic, which causes illness in 10 million people each year. These tools include effective vaccines, diagnostics and drug regimens.

Read More →

Astellas and TB Alliance enter into a new collaborative research agreement to identify lead compounds for the treatment of TB

TOKYO and NEW YORK (March 31, 2021) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TB Alliance (President and CEO: Mel Spigelman, M.D.), a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB) today announced that they have entered into a new collaborative research (“Hit-to-Lead PJ”) agreement to identify lead compounds for the treatment of TB.

Read More →

STAND clinical trial results published

March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal of Tuberculosis and Lung Disease.

Read More →

Amid global pandemic, TB treatment innovation advances at an unprecedented pace

PRETORIA (24 March 2021) — On World TB Day, as society reflects on how COVID-19 became the world’s most lethal infection in the span of a year, progress against tuberculosis (TB) can be found in the swift rollout of a short, all-oral regimen for highly drug-resistant TB infections.

Read More →

TB Alliance issues call for researchers to access TB biomarker repository

NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with Knowledge of Tuberculosis Biomarkers) database of high-quality patient specimens from late-stage TB drug clinical trials. In making this repository available, MARK-TB is enabling the discovery and qualification of biomarkers to speed clinical development of improved tuberculosis (TB) treatments for both drug-sensitive and multidrug-resistant TB, as well as potentially improving the care of TB patients.

Read More →

TB Alliance and GSK announce partnership to develop new TB therapeutics

NEW YORK (March 18, 2021) — TB Alliance and GSK have agreed to extend their longstanding collaboration to discover new compounds that can improve the treatment of tuberculosis (TB).

Read More →

ZebiAI and TB Alliance announce collaboration to apply ML-driven discovery platform to TB targets

TB Alliance to leverage ZebiAI’s platform to discover novel probe compounds for important tuberculosis targets, with options for drug discovery.

Read More →

New report reveals that R&D partnerships serving neglected communities have produced dozens of life-saving innovations since 2010

Novel approach for minimizing investment risks and stretching limited budgets has 375 innovations targeting infectious diseases under development.

Read More →

TB Alliance announces first patient dosed with TBAJ-587 in Phase 1 study

NEW YORK (December 15, 2020)—TB Alliance announced that on December 1, 2020 the first dose was administered to a patient as part of a new Phase 1 study of its novel compound TBAJ-587 in healthy adult volunteers. New treatment options are urgently needed, especially as there is growing resistance to available drugs to treat tuberculosis (TB).

Read More →

Patients in South Africa to access six-month, all-oral treatment for highly drug-resistant TB

Pretoria, 10 December 2020 — TB Alliance welcomes the Wits Health Consortium and the South African National Department of Health (DoH)’s announcement of an initiative to provide a new, shorter treatment regimen for people affected with highly drug-resistant forms of tuberculosis (TB). Funded by the United States Agency for International Development, a new clinical access program (CAP) will enroll 400 people in South Africa for treatment with a three-drug, six-month, all-oral regimen of bedaquiline, pretomanid and linezolid (known as the BPaL regimen) that has been shown to demonstrate a favorable outcome in 90% of patients.1 This treatment was developed by TB Alliance and studied in its pivotal Nix-TB trial, which was also conducted in South Africa.

Read More →

Page 1 of 9 · Total posts: 10

1 2 Last→